Aperio Group LLC reduced its position in Icon Plc (NASDAQ:ICLR) by 7.6% during the second quarter, Holdings Channel reports. The fund owned 14,136 shares of the medical research company’s stock after selling 1,162 shares during the period. Aperio Group LLC’s holdings in Icon Plc were worth $1,382,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Farmers & Merchants Investments Inc. raised its position in shares of Icon Plc by 11.5% in the first quarter. Farmers & Merchants Investments Inc. now owns 51,236 shares of the medical research company’s stock worth $4,085,000 after buying an additional 5,269 shares in the last quarter. World Asset Management Inc raised its position in shares of Icon Plc by 1.8% in the first quarter. World Asset Management Inc now owns 3,455 shares of the medical research company’s stock worth $275,000 after buying an additional 60 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Icon Plc by 43.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 234,818 shares of the medical research company’s stock worth $17,659,000 after buying an additional 70,654 shares in the last quarter. Legato Capital Management LLC raised its position in shares of Icon Plc by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Icon Plc during the first quarter worth $531,000. Institutional investors and hedge funds own 92.55% of the company’s stock.

Icon Plc (NASDAQ ICLR) traded down 0.61% during trading on Friday, reaching $101.40. 233,718 shares of the company’s stock traded hands. The firm has a market capitalization of $5.48 billion, a PE ratio of 20.57 and a beta of 0.60. The company has a 50-day moving average price of $100.50 and a 200 day moving average price of $89.05. Icon Plc has a one year low of $73.76 and a one year high of $109.32.

Icon Plc (NASDAQ:ICLR) last announced its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.04% and a return on equity of 26.34%. The company had revenue of $431 million for the quarter, compared to analysts’ expectations of $430.68 million. During the same quarter in the previous year, the company posted $1.14 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. On average, analysts anticipate that Icon Plc will post $5.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/icon-plc-iclr-stake-decreased-by-aperio-group-llc.html.

A number of equities analysts recently weighed in on ICLR shares. Zacks Investment Research lowered shares of Icon Plc from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. Evercore ISI upped their target price on shares of Icon Plc from $91.50 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, April 28th. Jefferies Group LLC restated a “hold” rating on shares of Icon Plc in a research report on Thursday, May 11th. ValuEngine lowered shares of Icon Plc from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st. Finally, Credit Suisse Group restated an “outperform” rating and set a $102.00 target price (up previously from $91.00) on shares of Icon Plc in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Icon Plc presently has an average rating of “Buy” and a consensus price target of $108.38.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.